These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25080789)

  • 1. [The immunologic predictors of effect of anti-B-cell therapy under rheumatoid arthritis].
    Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Nasonov EL
    Klin Lab Diagn; 2014 Mar; (3):48-52. PubMed ID: 25080789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis].
    Avdeev AS; Novikov AA; Aleksandrova EN; Panasiuk EIu; Nasonov EL
    Klin Med (Mosk); 2014; 92(1):28-34. PubMed ID: 25265656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical informativeness of detection of antibodies to citrullinated proteins under rheumatoid arthritis].
    Cherkasova MV; Novikov AA; Alexndrova EN; Karateev DE; Popkova TV; Luchikhina EL; Avdeeva AS; Nasonov EL
    Klin Lab Diagn; 2015 Feb; 60(2):46-9. PubMed ID: 26027260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
    Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
    Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B cell depletion with rituximab in patients with rheumatoid arthritis: Multiplex bead array reveals the kinetics of IgG and IgA antibodies to citrullinated antigens.
    Cambridge G; Leandro MJ; Lahey LJ; Fairhead T; Robinson WH; Sokolove J
    J Autoimmun; 2016 Jun; 70():22-30. PubMed ID: 27055777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
    Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
    PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
    Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
    Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion.
    Váncsa A; Szabó Z; Szamosi S; Bodnár N; Végh E; Gergely L; Szucs G; Szántó S; Szekanecz Z
    J Rheumatol; 2013 May; 40(5):565-71. PubMed ID: 23547216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab.
    de la Torre I; Leandro MJ; Edwards JC; Cambridge G
    Clin Exp Rheumatol; 2012; 30(4):554-60. PubMed ID: 22510323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis.
    Lindenberg L; Spengler L; Bang H; Dorner T; Maslyanskiy AL; Lapin SV; Ilivanova EI; Martinez-Gamboa L; Bastian H; Wittenborn E; Egerer K; Burmester GR; Feist E
    Arthritis Res Ther; 2015 Aug; 17(1):206. PubMed ID: 26268352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
    Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
    Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
    Lal P; Su Z; Holweg CT; Silverman GJ; Schwartzman S; Kelman A; Read S; Spaniolo G; Monroe JG; Behrens TW; Townsend MJ
    Arthritis Rheum; 2011 Dec; 63(12):3681-91. PubMed ID: 22127691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of power Doppler ultrasound for prediction of re-therapy with rituximab in rheumatoid arthritis: a prospective study of longstanding rheumatoid arthritis patients.
    Reiche BE; Ohrndorf S; Feist E; Messerschmidt J; Burmester GR; Backhaus M
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):204-16. PubMed ID: 23925935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.
    Ajeganova S; Fiskesund R; de Faire U; Hafström I; Frostegård J
    Clin Exp Rheumatol; 2011; 29(6):942-50. PubMed ID: 22153361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.
    Narvaez J; Díaz-Torné C; Ruiz JM; Hernandez MV; Torrente-Segarra V; Ros S; Rodriguez de la Serna A; Díaz-López C; Sanmartí R; Nolla JM
    Clin Exp Rheumatol; 2011; 29(6):991-7. PubMed ID: 22133052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease.
    Chen DY; Hsieh TY; Chen YM; Hsieh CW; Lan JL; Lin FJ
    Gerontology; 2009; 55(3):250-8. PubMed ID: 18849599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial.
    Mariette X; Rouanet S; Sibilia J; Combe B; Le Loët X; Tebib J; Jourdan R; Dougados M
    Ann Rheum Dis; 2014 Aug; 73(8):1508-14. PubMed ID: 23723317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients.
    Khan IH; Krishnan VV; Ziman M; Janatpour K; Wun T; Luciw PA; Tuscano J
    Cytometry B Clin Cytom; 2009 May; 76(3):159-68. PubMed ID: 18823005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of gender on response to rituximab in patients with rheumatoid arthritis: results from the Autoimmunity and Rituximab registry.
    Couderc M; Gottenberg JE; Mariette X; Pereira B; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Soubrier M;
    Rheumatology (Oxford); 2014 Oct; 53(10):1788-93. PubMed ID: 24821852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.